Gilead Sciences

News

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

News

EU ramps up supply of COVID-19 vaccine, drugs

The European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after signing a supply deal for up to 400 million doses of Johnson & Johns

News

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial

News

There are three types of white blood cells. T lymphocytes, B lymphocytes and natural killer cells.

Gilead’s Kite gains some height after second CAR-T approval ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T

News

Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is alr

News

Gilead finds survival boost with remdesivir with unorthodox ...

Gilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe COVID-19 infections, but adds controlled studies a

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

EU ramps up supply of COVID-19 vaccine, drugs

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Gilead’s Kite gains some height after second CAR-T approval ...

Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead finds survival boost with remdesivir with unorthodox ...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Gilead Sciences

Editor's Picks